Japan Alzheimer's Disease - Market Insight, Epidemiology and Market Forecast - 2032

Key Highlights

• The diagnosed prevalence of Alzheimer's disease has been increasing in Japan due to the increasing geriatric population and disease awareness.
• Increased awareness and advancements in a comprehensive understanding of the disease pathophysiology have led to the discovery of novel signaling pathways, due to which various diagnostic tools have evolved that have revolutionized disease diagnosis.
• The current treatment regime is mostly symptomatic, slows disease progression, and helps improve quality of life. It is not curative and is a mix of nonpharmacological and pharmacological approaches.
• Nonpharmacological therapies include cognitive stimulation, physical exercise, and social engagement. Caregiver support and education are crucial for managing the challenges associated with Alzheimer's.
• The major concern in understanding the market for Alzheimer's disease is that despite an extremely vibrant pipeline, assessing drugs' potential to enter the market is difficult due to high failure rates, as many potential therapies like gantenerumab, dabigatran, and verubecestat were unable to move past the trial phase.
• In Japan, the approval of Biogen/Eisai/BioArctic's LEQEMBI (lecanemab) in September 2023, an amyloid beta-protein inhibitor, has led to significant improvements from the traditional symptomatic treatment regime and quenched the thirst for disease-modifying therapy. This marks a major milestone and is a forward-looking step in addressing the unmet needs of patients with early Alzheimer's. This also paves the way for other biologics and drugs targeting the underlying disease pathology.
• In 2022, the market size of Alzheimer's disease in Japan accounted for approximately USD 864.1 million. It is expected to increase by 2032.

This “Alzheimer's Disease - Market Insights, Epidemiology, and Market Forecast - 2032” report delivers an in-depth understanding of Alzheimer's disease historical and forecasted epidemiology and the market trends in Japan.

The Alzheimer's disease market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted Japan Alzheimer's disease market size from 2019 to 2032. The report also covers current Alzheimer's disease treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.

Geography Covered

• Japan

Study Period: 2019-2032

Alzheimer's Disease Understanding and Treatment Algorithm

Alzheimer's Disease Overview

Alzheimer's disease, the most common type of dementia, is a progressive neurodegenerative disorder with a multifactorial pathogenesis. It is characterized by the gradual decline in cognitive and functional abilities, with individuals eventually losing the ability to undertake everyday tasks and function independently. Symptoms, for most people, first appear in their mid-60s. However, early disease may manifest in quadragenarians as well.

Although the symptoms vary widely, they develop slowly and worsen over time. Early signs may include forgetfulness, difficulty with problem-solving or completing familiar tasks, confusion, disorientation, and changes in mood or behavior. As the disease progresses, individuals may experience severe memory loss, language problems, impaired judgment, personality changes, and a decline in overall cognitive abilities.

Improved disease understanding demonstrates that the disease is characterized by two microscopic features, amyloid plaques and neurofibrillary agglomerates. The exact cause is mostly unknown, but research indicates that progressive cognitive decline is associated with the accumulation of amyloid-beta (Aß) and tau proteins. These deposits form amyloid protein plaques outside the brain cells and tangles of tau protein within the brain cells.

These plaques and tangles disrupt normal communication between brain cells, leading to progressive degeneration, memory deterioration, and death. Increasing age and family history are important risk factors.

Alzheimer's Disease Diagnosis

The pathogenesis is multifactorial, and due to the continuous discovery of novel signaling pathways, various diagnostic tools have revolutionized and improved disease diagnosis, making it more personalized. This has helped me understand the various possibilities of tau and amyloid deposition, neurodegeneration, and symptom manifestation.

Diagnosing Alzheimer's disease involves a comprehensive evaluation of medical history, cognitive tests, neurological exams, and assessment of behavioral and functional changes. There is no single test for the diagnosis. Clinical practice typically diagnoses it through a multidisciplinary workup based on patient history, clinical symptoms, and neuropsychiatric, physical, and functional assessments. Imaging (computed tomography, magnetic resonance imaging (MRI), positron emission tomography (PET) assessments, and blood tests are particularly important to rule out certain other causes of dementia. PET scans, especially amyloid scans, fluorodeoxyglucose imaging, and tau imaging, besides CSF biomarkers and blood-biomarker-based diagnosis, have improved the diagnosis manifold
Further details related to country-based variations are provided in the report.

Alzheimer's Disease Treatment

There is no cure for Alzheimer's disease, and the available treatments offer relatively small symptomatic benefits but remain palliative. The treatment is divided into pharmaceutical, psychosocial, and caregiving.

Psychosocial interventions are adjuncts to pharmaceutical treatment and are classified within behavior, emotion, cognition, or stimulation-oriented approaches. Cognitive stimulation therapy (CST), cognitive rehabilitation, simulated presence therapy, and music therapy effectively reduce behavioral and psychological symptoms.

Environment and lifestyle modifications, diet, and behavioral interventions are also important to improve the quality of life.

The drugs currently available to treat many symptoms associated with dementia are working by increasing activity levels of some brain neurotransmitters, such as acetylcholine, serotonin, and noradrenaline, or by reducing the activity of other neurotransmitters, such as glutamate and dopamine.

Pharmacological therapies for symptomatic treatment, such as acetylcholinesterase inhibitors (AChEIs) and NMDA receptor antagonists, memantine, have been available for over a decade. Recently, more targeted monoclonal antibodies that target amyloid beta-proteins have entered the Alzheimer's market space.

Donepezil, rivastigmine transdermal patch, and galantamine are three AChEIs approved for treating Alzheimer's disease. These are recommended to treat mild-to-advanced stages of Alzheimer's disease, yet their benefit-risk ratio is still being debated, with many countries not allowing their reimbursement.

Besides these, the NMDA receptor antagonist, memantine, has also been approved for treating Alzheimer's disease, but it is limited to moderate and severe cases and mostly in cases where cholinesterases have not been effective. Atypical antipsychotics, though not approved, are even commonly used to treat behavioral symptoms associated with Alzheimer's disease.

Alzheimer's Disease Epidemiology

As the market is derived using a patient-based model, the Alzheimer's disease epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of Alzheimer's disease, age-specific cases of Alzheimer's disease, gender-specific cases of Alzheimer's disease, and severity-specific cases of Alzheimer's disease in Japan from 2019 to 2032.

• In 2022, the total diagnosed prevalent cases of Alzheimer's disease in Japan were estimated to be approximately 3,954,710. These cases are projected to increase during the forecast period.
• As per the report estimates, Alzheimer's disease is more common in females than males. In 2022, the gender-specific diagnosed prevalent cases of Alzheimer's disease accounted for around 64% of females and 36% of males in Japan.

In 2022, the age-specific distribution of the disease suggests that the age cohort of 75-84 years accounted for the majority, nearly 51% of the cases, followed by =85 accounting for 32% of the cases, followed by others in Japan. These cases of Alzheimer's disease are expected to increase during the forecast period.

• According to estimates based on the publisher's epidemiology model for Alzheimer's disease, in Japan, in 2022, there were approximately 2,324,183 cases of MCI, 826,139 cases of mild dementia, 517,671 cases of moderate dementia, and 286,716 cases of severe dementia, which are expected to increase during the study period.

Alzheimer's Disease Drug Chapters

The drug chapter segment of the Alzheimer's disease report encloses a detailed analysis of Alzheimer's disease - currently used drugs and mid-stage (Phase II and Phase I) pipeline drugs. It also helps understand the Alzheimer's disease clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

LEQEMBI (lecanemab): Biogen/Eisai/ BioArctic

LEQEMBI (lecanemab) is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibrils) and insoluble forms of Aß. The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer's disease. LEQEMBI reduces amyloid beta plaques and is indicated for treating mild cognitive impairment or mild dementia stage of Alzheimer's disease. The US FDA has granted the drugs breakthrough therapy designation and FTD.

The recommended dosage of LEQEMBI is 10 mg/kg, diluted and then administered via IV infusion for approximately 1 h, once every 2 weeks, to eligible patients with confirmed presence of Aß pathology before initiating treatment. Enhanced clinical vigilance for amyloid-related imaging abnormalities (ARIA) is recommended during the first 14 weeks of treatment with LEQEMBI.

In September 2023, Japan's MHLW approved Biogen, Eisai, and BioArctic's LEQEMBI (lecanemab) as a treatment for slowing the progression of MCI and mild dementia due to Alzheimer's disease. In July 2023, the US FDA converted accelerated approval to traditional approval following a determination that a confirmatory trial verified clinical benefit. LEQEMBI is the first amyloid beta-directed antibody targeting the disease process to be converted from accelerated approval to traditional approval.

Biogen and Eisai have submitted an application to the European Medicines Agency (EMA) for approval of lecanemab in the EU and further aim to submit a Biologics License Application (BLA) with the US FDA for LEQEMBI SC formulation by March 2024 and are conducting trials for the same.

Emerging Drugs

ADUHELM (aducanumab): Biogen/Eisai

ADUHELM is a human IgG1 mAb directed against amyloid beta (Aß) protein, one of the hallmarks of Alzheimer's disease. It exerts its mechanism of action by crossing the blood-brain barrier and selectively targeting and binding aggregated soluble oligomers and insoluble fibril conformations of Aß plaques in the brain.

The drug is approved by the US FDA for use in Alzheimer's disease in patients with mild cognitive impairment or mild dementia stage of the disease. The recommended maintenance dosage is 10 mg/kg administered as an IV over approximately 1 h every 4 weeks. ADUHELM is administered as an IV infusion over approximately 1 h every 4 weeks and at least 21 days apart. The most common side effects of ADUHELM include swelling in areas of the brain, with or without small spots of bleeding in the brain or on the surface of the brain, amyloid-related imaging abnormalities (ARIA), and headache.

In April 2022, Biogen withdrew its marketing authorization application (MAA) for ADUHELM from the EMA. In December 2021, Biogen and Eisai faced a refusal to approve ADUHELM from the Japanese regulators due to insufficient data.

Note: Detailed emerging therapies assessment will be provided in the final report.

Drug Class Insights

Alzheimer's disease, the most common type of dementia, is a progressive neurodegenerative disorder with a multifactorial pathogenesis. It is characterized by a gradual decline in cognitive and functional abilities, with individuals eventually losing the ability to undertake everyday tasks and function independently. Symptoms of Alzheimer's disease, for most people, first appear in their mid-60s. However, early disease may manifest in quadragenarians as well. Early diagnosis becomes difficult with the exact cause mostly unknown and limited early manifestation. The multifactorial nature of the disease further compounds this. Earlier diagnosis is important for enabling symptomatic therapies, treating behavioral symptoms, and adopting lifestyle changes.

The current treatment regime is mostly symptomatic, slows disease progression, and helps improve quality of life. It is not curative and is a mix of nonpharmacological and pharmacological approaches. Most drugs to treat symptoms work by increasing activity levels of some brain neurotransmitters, such as acetylcholine, serotonin, and noradrenaline, or by reducing the activity of other neurotransmitters, such as glutamate and dopamine.

Pharmacological therapies for symptomatic treatment, such as acetylcholinesterase inhibitors (AChEIs) and NMDA receptor antagonist memantine, have been available for over a decade. Recently, more targeted monoclonal antibodies that target amyloid beta-proteins have entered the Alzheimer's market space.

The three AChEIs, donepezil, rivastigmine, and Galantamine, are approved with comparable therapeutic effects. These are recommended to treat mild-to-advanced stages of Alzheimer's disease, yet their benefit-risk ratio is still being debated. They work by inhibiting the activity of acetylcholinesterase, an enzyme that breaks down acetylcholine, a neurotransmitter involved in memory and cognitive function. By inhibiting acetylcholinesterase, these medications increase the levels of acetylcholine in the brain, potentially improving cognitive symptoms in Alzheimer's disease.

Alzheimer's Disease Market Outlook

The drugs currently available to treat many symptoms associated with dementia are working by increasing activity levels of some brain neurotransmitters, such as acetylcholine, serotonin, and noradrenaline, or by reducing the activity of other neurotransmitters, such as glutamate and dopamine. Due to associated side effects, it is also important to personalize dementia symptomatic therapeutics considering patients' comorbidities and their respective therapies. Effects on cardiac function, drug elimination, and other interactions should be assessed case by case.

There are three approved AChEIs, donepezil, rivastigmine, and Galantamine are used in more than 60 countries to treat mild-to-advanced stages of Alzheimer's disease. These are donepezil, rivastigmine transdermal patch, and galantamine. The therapeutic effects of donepezil, rivastigmine, and galantamine are fairly comparable. Their effectiveness is considered modest and temporary and needs to be regularly re-evaluated. Though these have demonstrated symptomatic benefits in rigorous double-blind, placebo-controlled randomized clinical trials, there are also associated side effects. However, their benefit-risk ratio is still being debated, due to which some countries, notably France, have chosen not to allow their reimbursement by the public health sector.

The NMDA antagonist, memantine, works in another brain cell communication network and slows the progression of symptoms in individuals with moderate to severe Alzheimer's disease. It can be given as monotherapy or combined with a cholinesterase inhibitor.

The current market has been covered by the symptomatic treatment that includes different pharmacological agents used in Japan, which presents minor variations in the overall prescription pattern. LEQEMBI (lecanemab), galantamine, rivastigmine, donepezil, memantine, and a combination of memantine and acetylcholinesterase inhibitors are the major drugs considered for symptomatic treatment in the forecast model.

Key players Anavex Life Sciences, Alzheon, Athira Pharma, Annovis Bio, Eli Lilly, BioVie, AB Science, Novo Nordisk, Cassava Sciences, TauRx Therapeutics, KeifeRx, AriBio, Cerecin, Eisai, and others are evaluating their lead candidates in different stages of clinical development. They aim to investigate their products for the treatment of Alzheimer's Disease.

• The total market size of Alzheimer's disease in Japan was approximately USD 914.5 million in 2022 and is projected to increase during the forecast period (2023-2032).
• As per the report estimates, in Japan, cholinesterase inhibitors (donepezil, rivastigmine, and Galantamine) and NMDA receptor antagonist (memantine) accounted for USD 869.8 million and USD 21.9 million in 2022. Among cholinesterase inhibitors, donepezil had the highest share (of all the therapies), with nearly 67% of the total revenue in the class, while rivastigmine generated USD 67.6 million in 2022.
• According to the publisher's estimates, Biogen and Eisai's LEQEMBI, which received approval from MHLW in September 2023, is projected to grow substantially during the forecast period and revenue capture around 2.8% of the total Japanese Alzheimer's disease market by 2032.
• Various therapies like Anavex Life Sciences's ANAVEX2-73 (blarcamesine), Alzheon's ALZ-801 (valiltramiprosate), Athira Pharma's fosgonimeton (ATH-1017), Annovis Bio's buntanetap, Eli Lilly's donanemab (LY3002813), BioVie's NE3107, Cassava Sciences' simufilam (PTI-125), and TauRx Therapeutics' hydromethylthionine mesylate (TRx0237) among others are anticipated to enter the market during the forecast period.
• Eli Lilly's donanemab (LY3002813) is projected to be the first emerging therapy to enter the market by 2024. It is an amyloid ß protein inhibitor that will compete with Biogen/Eisai/BioArctic's LEQEMBI. With one of the best efficacy results, wherein the therapy led to a 39% lower risk of progressing to the next stage of the disease, the drug is projected to have a slow-medium uptake. High costs will translate to higher revenue, and it will attain its peak share by the seventh year. Despite product-related safety concerns, the drug will perform well during the forecast period, capturing nearly 26.1% of the total Alzheimer's market by 2032.
• Another Eli Lilly product, remternetug (LY3372993), a mAb that targets toxic amyloid plaques linked to the onset of Alzheimer's disease, is being investigated in IV and SC forms. The candidate is projected to capture around 0.1% of Japan's Alzheimer's disease market in its launch year 2029.
• TauRx Therapeutics' Hydromethylthionine mesylate (HMTM)/TRx0237, an orally administered therapy for early Alzheimer's, has reported no safety issues. It is the first novel target drug that is not biological and has the potential to be one of the best performers.
• BioVie's NE3107, Cassava Sciences' simufilam (PTI-125), Anavex Life Sciences' ANAVEX2-73 (blarcamesine), Alzheon's ALZ-801 (valiltramiprosate) are next in line with projected entry by 2027. Alzheon's ALZ-801, another FDA-designated product, is an orally administered amyloid beta-protein and oligomer formation inhibitor. The drug has demonstrated excellent efficacy in its trial, but high doses and long treatment duration may affect its potential. With a slow-medium uptake, it will attain its peak share by the eighth year.
• Anavex Life Sciences' ANAVEX2-73 (blarcamesine), a SIGMAR1 activator and muscarinic receptor modulator for treating early Alzheimer's patients, has the potential to establish itself in the crowded market space. The trials have demonstrated that about 84% of the treated patients have improved cognition. A low-dose regime might ensure better compliance. All these factors point to the drug performing well in the Alzheimer's market. The drug will peak by the seventh year with a medium uptake.
• Athira Pharma's fosgonimeton (ATH-1017), a hepatocyte growth factor and MET receptor stimulant, has demonstrated excellent improvements in cognitive score in its trial. A low dose favorable safety profile places the drug in a strong position, which is anticipated to have a medium uptake.

Alzheimer's Disease Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2019-2032. For example, Annovis Bio's buntanetap, a translational inhibitor of neurotoxic aggregating proteins, with an anticipated entry by 2029 in the US, is predicted to have a slow-medium uptake during the forecast period.

Further detailed analysis of emerging therapies drug uptake in the report.

Alzheimer's Disease Pipeline Development Activities

The report provides insights into therapeutic candidates in late-stage development, including Phase III and Phase II/III. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for emerging therapies for Alzheimer's disease.

KOL Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on the Alzheimer's disease evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including Medical/scientific writers, Medical Professionals, Professors, Directors, and Others.

This analysts connected with 30+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in Japan. Centers like the National Institute of Infectious Diseases, Kyoto University, Japanese Society of Psychiatry and Neurology, Yokohama Brain and Spine Center, and Japan Society for Dementia Research were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or Alzheimer's disease market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Physician's View

According to the primary research analysis, LEQEMBI's approval will change the treatment regime and market dynamics for Alzheimer's. Though not curative, this is the first approved disease-modifying therapy in Japan for early Alzheimer's patients, as it delays the progression. Though the drug has potential, there are certain hurdles, like testing requirements on the drug's prescribing label and risk warning, which push one to keep caution. The results in delaying disease progression have done well, and awareness needs to be generated to ensure drug usage.

Qualitative Analysis

The publisher performs Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. To analyze the effectiveness of these therapies, have calculated their attributed analysis by giving them scores based upon change from baseline in the ADCS-ADL scale, ADAS-Cog scale, and Clinical Dementia Rating (CDR) - global score results, among others. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The therapies' safety is evaluated wherein treatment-related adverse events along with serious adverse events were majorly observed, besides the occurrence of amyloid-related imaging abnormalities (ARIA). It sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

The National Health Insurance Drug List of the Japanese Ministry of Health, Labor and Welfare has enlisted donepezil (1,190,012), memantine (1,190,018), galantamine (1,190,019), and rivastigmine (1,190,700).

In September 2023, LEQEMBI (lecanemab), a humanized anti-soluble aggregated amyloid-beta (Aß) monoclonal antibody, was approved in Japan as a treatment for slowing the progression of MCI and mild dementia due to Alzheimer's disease. Following the approval, the drug reimbursement policy has been debated. Considering its large patient population, the Central Social Insurance Medical Council (Chuikyo) discussed how best to finance the drug. A key focus of the first discussion was if LEQEMBI was priced similarly in Japan to its price in the US, it would be eligible for the new “mega-seller” rule.

The Central Social Insurance Medical Council (Chuikyo) General Meeting Discussion from November revealed that drug prices were calculated using the usual calculation method (similar drug efficacy comparison method or cost calculation method), and the drug prices of LEQEMBI intravenous injection 200 mg and LEQEMBI intravenous injection 500 mg were announced. Further, the drug pricing organization will create a pricing proposal, and based on that, the Chuikyo general meeting will decide whether the drug will be included in the drug price standards (insurance coverage) by 24th December 2023 at the latest.

The report provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenarios, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report

• The report covers a segment of key events, an executive summary, descriptive overview of Alzheimer's disease, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines have been provided.
• Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
• A detailed review of the Alzheimer's disease market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind the approach is included in the report, covering the Japan drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the Japanese Alzheimer's disease market.

Alzheimer's Disease Report Insights

• Patient Population
• Therapeutic Approaches
• Alzheimer's Disease Pipeline Analysis
• Alzheimer's Disease Market Size and Trends
• Existing and Future Market Opportunity

Alzheimer's Disease Report Key Strengths

• Ten Years Forecast
• Japan Coverage
• Alzheimer's Disease Epidemiology Segmentation
• Key Cross Competition
• Conjoint analysis
• Drugs Uptake and Key Market Forecast Assumptions

Alzheimer's Disease Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

Key Questions Answered

Market Insights

• What was the total market size of Alzheimer's disease, the market size of Alzheimer's disease by therapies, market share (%) distribution in 2019, and what would it look like by 2032? What are the contributing factors for this growth?
• How will donanemab (LY3002813), hydromethylthionine mesylate (HMIM)/TRx0237, ALZ-801 (valiltramiprosate), fosgonimeton (ATH-1017), and others affect the treatment paradigm of Alzheimer's disease?
• How will LEQEMBI (lecanemab) compete with other off-label symptomatic and emerging treatments?
• Which drug is going to be the largest contributor by 2032?
• What are the prices of different therapies in Japan?
• How would future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights

• What are the disease risks, burdens, and unmet needs of Alzheimer's disease? What will be the growth opportunities in Japan with respect to the patient population pertaining to Alzheimer's disease?
• What is the historical and forecasted patient pool of Alzheimer's disease in Japan?
• What patient population is affected by different severity stages of Alzheimer's disease in Japan?
• What factors are contributing to the growth of Alzheimer's disease cases?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current options for the treatment of Alzheimer's disease?
• How many companies are developing therapies for the treatment of Alzheimer's disease?
• How many emerging therapies are in the mid-stage and early stage of development for treating Alzheimer's disease?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• What is the cost burden of current treatment on the patient?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the accessibility issues of approved therapy in Japan?
• What is Japan's historical and forecasted market for Alzheimer's disease?

Reasons to Buy

• The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the Alzheimer's disease market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunity in Japan and the growth potential over the coming years.
• Historical and current patient share distribution is based on real-world prescription data in Japan.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy